In vitro screening in cervical cancer cells of anti-cancer compounds derived from Cameroonian plants

Show simple item record

dc.contributor.advisor Moela, Pontsho
dc.contributor.coadvisor October, Natasha
dc.contributor.postgraduate Bona, Angela
dc.date.accessioned 2023-02-13T10:01:15Z
dc.date.available 2023-02-13T10:01:15Z
dc.date.created 2023-04
dc.date.issued 2023
dc.description Dissertation (MSc (Genetics))--University of Pretoria, 2023. en_US
dc.description.abstract Cervical cancer is a public female health burden, especially in Africa, and is mainly caused by infection with HPV in which unvaccinated cases allow the development of malignancy and ultimately angiogenesis and metastasis. Apoptosis, which is often evaded in cancer, is a popular targeted mechanism of current and potential anti-cancer drugs. However, cytotoxic cervical cancer therapies, such as platinum-based chemo- and radiotherapy, also elicits non-selective and systemic toxicity and temporarily subdues advanced cancers into remission with unexpected relapse. In addition, treatments utilizing an apoptotic anti-cancer approach induce necrosis concomitantly which result in inflammatory side-effects. This necessitates the screening of alternative treatment regimens, such as plant secondary metabolites and their various combinations for discovery of new anti-cancer compounds or unprecedented anti-cancer potentials of old compounds. Therefore, compounds isolated from four Cameroonian plants, namely Cassia arereh, Distemonanthus benthamianus, Echinops gracilis and Rhabdophyllum affine, were screened for their individual cytotoxicities against cervical cancer cells. Compounds that showed sufficient anti-cancer and cancer-selective potentials were then further studied in combination. Initial screening revealed a terpenoid and flavonoid isolated from C. arereh (CAE21) and E. gracilis (EGF25), respectively. CAE21 and EGF25 induced strong apoptotic responses especially in combination with no necrotic response. In addition, CAE21 showed optimal oral bioavailability in silico, although EGF25 did not show the same drug-likability. CAE21 and EGF25 also demonstrated molecular bioactivities of 0.18 and 0.14 as GPCR and nuclear receptor ligands, respectively. Despite the demonstrated anti-cancer potential of CAE21 and EGF25, reproducible effects in more biological cancer models and further elucidation of apoptotic and molecular mechanisms are needed. en_US
dc.description.availability Unrestricted en_US
dc.description.degree MSc (Genetics) en_US
dc.description.department Genetics en_US
dc.description.sponsorship National Research Foundation (NRF), Grant UID 113980. en_US
dc.description.sponsorship South African Medical Research Council (A1A979). en_US
dc.identifier.citation Bona, A 2023, In vitro screening in cervical cancer cells of anti-cancer compounds derived from Cameroonian plants, MSc Dissertation, University of Pretoria, Pretoria, viewed yymmdd https://repository.up.ac.za/handle/2263/89435 en_US
dc.identifier.doi https://doi.org/10.25403/UPresearchdata.22068350 en_US
dc.identifier.other A2023
dc.identifier.uri https://repository.up.ac.za/handle/2263/89435
dc.identifier.uri DOI: 10.25403/UPresearchdata.22068350
dc.language.iso en en_US
dc.publisher University of Pretoria
dc.rights © 2022 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria.
dc.subject UCTD en_US
dc.subject Cervical cancer en_US
dc.subject Anti-cancer compound en_US
dc.subject Plant compound en_US
dc.subject Compound combination en_US
dc.subject Drug discovery en_US
dc.title In vitro screening in cervical cancer cells of anti-cancer compounds derived from Cameroonian plants en_US
dc.type Dissertation en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record